MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with ...
The following is a summary of “BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma,” published in ...
The TRX103 Phase 1/2a clinical trial is being led by Maria Grazia Roncarolo, MD, co-founder, president and head of R&D at Tr1X, with patients enrolling at leading stem cell transplant centers across ...
News Medical on MSN1d
HLA-DRB1 molecule offers potential target for CAR therapy in relapsed acute myeloid leukemia post-transplantationOne main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells. Therefore, many ...
Taconic Biosciences prioritizes accessibility and efficiency in preclinical research. Unlike other providers, Taconic does ...
A research team led by Prof. ZHAN Cheng from the University of Science and Technology of China (USTC), and Chief Physician ZHU Xiaoyu from the First Affiliated Hospital of USTC has identified how stem ...
A research team has identified the impact of stem cell infusion timing on the incidence and severity of acute ...
A team of scientists led by Northwestern Medicine investigators have uncovered new details about a deadly heart condition ...
Monzr M. Al Malki, MD, discussed data for AlloHeme, a blood test used to detect risk of relapse post-transplant in patients ...
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback